Down’s screening test 21-trisomy critical risk, indicating that the Down’s screening result is between low and high risk, indicating that the fetus may have Down’s syndrome. Down’s syndrome screening is an abbreviation for prenatal screening for Down’s syndrome, which is performed by collecting blood from pregnant women and testing their serum concentrations of alpha-fetoprotein, chorionic gonadotropin and free estriol. The results of the Down screening test show a critical risk of trisomy 21, which does not confirm the diagnosis of Down syndrome in the fetus. It is recommended that pregnant women have a non-invasive DNA test, which is more accurate than the results of the Down screening test by isolating the DNA components of the fetal blood from the pregnant woman’s blood and observing whether there are abnormalities in the fetal DNA. If the non-invasive DNA suggests a high risk, an amniocentesis test is needed to confirm the diagnosis, but there is a risk of miscarriage with amniocentesis, with a risk of about 0.5%. If all the above tests are fine, the pregnancy can continue, while paying attention to rest and having regular pregnancy checkups. If the test results indicate that the fetus is Down’s syndrome, the pregnant woman is advised to stop the pregnancy in time. There is a time limit for Down’s syndrome screening, which is usually performed between 11-13 weeks of pregnancy in early pregnancy and between 16-20 weeks of pregnancy in middle pregnancy.
Support Us
Discussion
Share your experience, or seek help from fellow patients.
